Cara Therapeutics reported $8.08M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Cara Therapeutics USD 8.08M 3.18M Sep/2026
Cassava Sciences USD 41.95M 1.79M Sep/2026
Chugai Pharma JPY 256.57B 135.62B Sep/2026
Cipla INR 69.77B 366.6M Sep/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.63M 596K Jun/2026
CSL USD 4.61B 207M Dec/2025
Grifols EUR 2.37B 156.97M Dec/2025
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
J&J USD 55.46B 562M Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Pacira USD 126.1M 4.08M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
RedHill Biopharma USD 25.56M 6.34M Jun/2026
Supernus Pharmaceuticals USD 285.4M 61.98M Sep/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025